Swiss pharma giant Roche has announced positive Phase I/II data on NXT007 in people with hemophilia A, supporting its ...

Chugai Pharma presents positive data from NXTAGE phase I/II study of NXT007 in people with haemophilia A at ISTH 2025 Congress: Tokyo Tuesday, June 24, 2025, 13:00 Hrs [IST] Chuga ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show ...

CHICAGO, IL, USA I June 2, 2025 I ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its next-generation CD47-targeting ...

Tel Aviv, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon ...

Italian newspapers are reporting a historic moment in Franco-Italian economic relations: Italy is no longer the smaller partner. While Italy’s gross domestic product (GDP) reached only €2.19 trillion ...

SUZHOU, China I May 5, 2025 I CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that a poster presentation ...

During the earnings call, analysts inquired about Roche’s strategies for mitigating US tariffs and the dynamics of the Vobismo market. The company also detailed its plans for next-generation ...

NXT007 was engineered based on Hemlibra and has enhanced binding affinities, extended half-life, and Roche expects it to be administered through a low volume and infrequent subcutaneous injection ...

Phase II data for NXT007 will be shared in an upcoming medical congress and as covered as part of the IR event on June 23. So up next, let’s head over to our neurology -- our neurology franchise.